GraftBolt®: Improving success rate for ACL tibial fixation
The anterior cruciate ligament (ACL) helps stabilise the knee joint when changing direction. ACL injury affects 1 in 3,500 people, resulting in 95,000 new ACL ruptures per year.
The ACL is commonly reconstructed using the patient’s own hamstring tendons to form a quadruple graft that is secured in the tibia and femur. The most common way of securing the tendon graft in the tibia is to use an interference screw, or the IntrafixTM tibial system.
However, the failure rate of ACL reconstruction is between 5% and 25% and the main cause of graft failure in the early post-operative period is loss of graft fixation within the tibia.
A new ACL tibial fixation device was developed by Mr Martyn Snow, an Orthopaedic Registrar at University Hospital of South Manchester NHS Foundation Trust in collaboration with mechanical engineers, Dr Bin Wang and Dr Mahmoud Chizari, based at The University of Manchester.
The initial development work and testing was funded by a TRUSTECH Pathfinder Development Fund Award and some funding from The University of Manchester.
The partnership between the NHS Trust, The University, the company and TrusTECH that led to the development of the device was recognised with a PraxisUnico Collaborative Impact Award in June 2011.
GraftBolt® is being manufactured and sold under licence by Arthrex Inc.
Find out more: www.arthrex.com